In a study by Urner-Bloch et al., 32 patients with advanced cutaneous melanoma were treated only with the selective MEK inhibitor binimetinib; or treated in combination with B-RAF inhibitors and it is found that these chemotherapeutics can cause impermanent retinopathy [11]. This evidence concerns the gene BRAF and cutaneous melanoma.